Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Soon

<< Previous

Bullboard Posts

Next >>

Comment by Bvukmanicon Feb 03, 2021 10:09am

110 Views

Post# 32457374

RE:Soon

Can I ask why? I see a lot of to the moon posts, but nothing with any substance. For example, QLGN has a broad antiviral prophylaxis that was found to be effective against coronaviruses (among others) in preclinical studies at University of Louisville's Center for Infectious Disease. They've already met with FDA who recommended a phase 2 study. Zacks recently published a report which are usually optimistic - EUA in 2022, peak sales of $100mm, 15% discount rate, NPV of only $10mm.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market